Latest Headlines

Latest Headlines

Shire's Ornskov signals a pause in dealmaking after a $50B buyout streak

Shire, awaiting the close of its $32 billion merger with Baxalta, is planning to move away from its penchant for acquisitions and focus on developing and launching products, CEO Flemming Ornskov said.

With Baxalta in hand, Shire's not looking to buy. But sell? Maybe

Shire's been somewhat of an M&A machine as of late, making a string of deals that most recently included its largest-ever, Baxalta. But it's an old standby that helped the company beat analyst estimates for Q4.

Shire's self-described blockbuster eye drug lines up for FDA do-over

Shire's once-rejected treatment for dry eye disease has another date with the FDA, supported by new data the company believes will get the drug on the market and eventually help bring in more than $1 billion in annual revenue.

Shire's back on track with its dry-eye threat to Allergan's Restasis

It's been just over three months since the FDA handed Shire a rejection for dry eye candidate lifitegrast, giving rival Allergan a boost in the process. But now, the company is back with a resubmission.

Shire gets back on track with once-rejected eye drug

Shire has resubmitted the once-rejected eye treatment lifitegrast for FDA approval, handing in new data the company hopes will get its self-described blockbuster drug onto the market.

Can Shire make the most of Baxalta's hemophilia meds?

Shire CEO Flemming Ornskov says his own goals for cost savings, postmerger with Baxalta, are higher than the company's stated $500 million.

Shire CEO thinks he can beat $500M in postmerger cost savings

Shire may have clinched its $32 billion deal to buy Baxalta, but not everyone is breaking out the confetti. Some analysts aren't sold on the tie-up, saying they expected more in the way of savings and still are perplexed by what Baxalta brings to the table.

Shire to take on hemophilia marketing with long-sought Baxalta buy

Baxalta and its portfolio of hemophilia meds are finally destined to join the fold at Shire. Monday, the two companies announced a $32 billion tie-up after a months-long pursuit by the Dublin drugmaker. 

Single-minded Shire finally pins down Baxalta with $32B deal

The new year has its first megadeal agreement, thanks to Shire and Baxalta. On Monday, the two finally announced a $32 billion tie-up after a months-long pursuit by the Dublin drugmaker.

Wait for it--Shire could finally announce $32.5B Baxalta deal by Monday

Could Shire's months-long pursuit of Baxalta finally be coming to a close? That's the word from  Reuters, which says the Dublin drugmaker is preparing to announce its acquisition--valued at about $32.5 billion--as early as Monday.